HK1210949A1 - Combinations and uses thereof - Google Patents

Combinations and uses thereof

Info

Publication number
HK1210949A1
HK1210949A1 HK15111752.8A HK15111752A HK1210949A1 HK 1210949 A1 HK1210949 A1 HK 1210949A1 HK 15111752 A HK15111752 A HK 15111752A HK 1210949 A1 HK1210949 A1 HK 1210949A1
Authority
HK
Hong Kong
Prior art keywords
combinations
Prior art date
Application number
HK15111752.8A
Other languages
English (en)
Chinese (zh)
Inventor
簡.恩德爾
利莎.羅杰克加爾
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HK1210949A1 publication Critical patent/HK1210949A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
HK15111752.8A 2012-09-25 2015-11-30 Combinations and uses thereof HK1210949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705172P 2012-09-25 2012-09-25
US201361774595P 2013-03-08 2013-03-08
PCT/EP2013/069858 WO2014048921A1 (en) 2012-09-25 2013-09-24 Combinations and uses thereof

Publications (1)

Publication Number Publication Date
HK1210949A1 true HK1210949A1 (en) 2016-05-13

Family

ID=49237209

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111752.8A HK1210949A1 (en) 2012-09-25 2015-11-30 Combinations and uses thereof

Country Status (23)

Country Link
US (1) US9579378B2 (ko)
EP (1) EP2900232B1 (ko)
JP (1) JP6426093B2 (ko)
KR (1) KR102171669B1 (ko)
CN (1) CN104684552B (ko)
AU (1) AU2013322806C1 (ko)
BR (1) BR112015006731A2 (ko)
CA (1) CA2885792C (ko)
DK (1) DK2900232T3 (ko)
ES (1) ES2658953T3 (ko)
HK (1) HK1210949A1 (ko)
HR (1) HRP20171964T1 (ko)
HU (1) HUE036518T2 (ko)
IL (1) IL237926B (ko)
LT (1) LT2900232T (ko)
MX (1) MX368288B (ko)
NZ (1) NZ706147A (ko)
PL (1) PL2900232T3 (ko)
PT (1) PT2900232T (ko)
RU (1) RU2650618C2 (ko)
SG (1) SG11201502163QA (ko)
WO (1) WO2014048921A1 (ko)
ZA (1) ZA201501980B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101472250B1 (ko) 2005-10-12 2014-12-11 모르포시스 아게 인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
SG11201701867SA (en) * 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA43187B1 (fr) 2015-11-03 2021-02-26 Janssen Biotech Inc Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
IL260750B2 (en) * 2016-03-04 2024-02-01 Morphosys Ag Clinical evaluation of protein-M response in multiple myeloma
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
ES2541489T3 (es) 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
CN101218256B (zh) * 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
KR101472250B1 (ko) * 2005-10-12 2014-12-11 모르포시스 아게 인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링
US9040050B2 (en) 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
WO2011154453A1 (en) * 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
BR112013006769B1 (pt) * 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
AU2012276037A1 (en) 2011-06-29 2014-02-13 Mayo Foundation For Medical Education And Research Small molecule CD38 inhibitors and methods of using same
CN105407921A (zh) 2013-03-13 2016-03-16 赛诺菲 包含抗cd38抗体和卡非佐米的组合物
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b

Also Published As

Publication number Publication date
CA2885792C (en) 2021-09-28
PL2900232T3 (pl) 2018-05-30
IL237926B (en) 2020-04-30
NZ706147A (en) 2018-10-26
AU2013322806A1 (en) 2015-04-09
RU2650618C2 (ru) 2018-04-16
SG11201502163QA (en) 2015-04-29
CA2885792A1 (en) 2014-04-03
US20150238603A1 (en) 2015-08-27
ZA201501980B (en) 2017-11-29
ES2658953T3 (es) 2018-03-13
HRP20171964T1 (hr) 2018-02-23
BR112015006731A2 (pt) 2017-07-04
US9579378B2 (en) 2017-02-28
EP2900232B1 (en) 2017-11-15
AU2013322806B2 (en) 2017-11-30
CN104684552A (zh) 2015-06-03
IL237926A0 (en) 2015-05-31
AU2013322806C1 (en) 2018-03-08
CN104684552B (zh) 2018-08-07
LT2900232T (lt) 2018-02-26
JP2015530399A (ja) 2015-10-15
JP6426093B2 (ja) 2018-11-28
KR20150090030A (ko) 2015-08-05
HUE036518T2 (hu) 2018-07-30
MX368288B (es) 2019-09-27
EP2900232A1 (en) 2015-08-05
DK2900232T3 (en) 2018-02-05
RU2015110981A (ru) 2016-11-20
MX2015003589A (es) 2015-08-12
WO2014048921A1 (en) 2014-04-03
PT2900232T (pt) 2018-02-09
KR102171669B1 (ko) 2020-10-30

Similar Documents

Publication Publication Date Title
IL269045B (en) Aptamers and their uses
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1203493A1 (en) Substituted azabicycles and use thereof
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
HK1210949A1 (en) Combinations and uses thereof
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
EP2938415A4 (en) MATERIALS AND METHOD
PL2882708T3 (pl) Nowe związki i ich zastosowania
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
SI2830587T1 (sl) Sestavek za zaščito in uravnoteženje kože
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201222342D0 (en) Compounds and uses thereof
GB201214749D0 (en) Compounds and their uses
EP2922862A4 (en) COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF
GB201215414D0 (en) Composition and use
GB201207075D0 (en) New compounds and uses
GB201206973D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses